Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Crinetics Pharmaceuticals (Nasdaq: CRNX) has announced that its Founder and CEO, Scott Struthers, Ph.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference. The event will take place in San Francisco, CA on Tuesday, January 14, 2025, at 4:30 p.m. Pacific Time.

To access the live webcast of the presentation, interested parties can click a provided link. Additionally, the archived webcast will be available on the Events & Presentations page in the Investors section of Crinetics' website at www.crinetics.com/events.

For those who wish to arrange a 1x1 meeting with the management, it is advised to contact their conference representative.

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 43^rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Tuesday, January 14, 2025 at 4:30 p.m. Pacific Time.

To access the live webcast, click here. The archived webcast will also be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website at www.crinetics.com/events.

If you are interested in arranging a 1x1 meeting with management, please contact your conference representative.

ABOUT CRINETICS PHARMACEUTICALS
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant, an investigational, first-in-class, oral ACTH antagonist that is currently completing Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing’s disease. All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.

Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340

Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075

FAQ

When will Crinetics Pharmaceuticals present at the J.P. Morgan Healthcare Conference?

Crinetics Pharmaceuticals will present on Tuesday, January 14, 2025, at 4:30 p.m. Pacific Time.

Who will represent Crinetics Pharmaceuticals at the J.P. Morgan Healthcare Conference?

Scott Struthers, Ph.D., Founder and CEO of Crinetics Pharmaceuticals, will present at the conference.

Where can I watch the Crinetics Pharmaceuticals presentation at the J.P. Morgan Healthcare Conference?

You can access the live webcast through a link provided in the announcement or watch the archived webcast on the Events & Presentations page in the Investors section of Crinetics' website.

What is the stock symbol for Crinetics Pharmaceuticals?

The stock symbol for Crinetics Pharmaceuticals is CRNX.

How can I arrange a 1x1 meeting with Crinetics Pharmaceuticals' management at the J.P. Morgan Healthcare Conference?

To arrange a 1x1 meeting with Crinetics Pharmaceuticals' management, please contact your conference representative.

Where is the 43rd Annual J.P. Morgan Healthcare Conference being held?

The conference is being held in San Francisco, CA.